Program Book
|
| View PDF (1,637
KB, 115 Pages) |
| It has been 20 years since the FDA licensed the first test for HTIV-III/LAV
antibody in 1985. Remarkable developments in the field of serologic and
nucleic acid testing have occurred since that time; the introduction of
one-step rapid HIV tests represent the largest shift in the platform for
HIV diagnostic testing in two decades. However, the central question remains
the same, posed during CDC’s 1987 workshop in Atlanta: what is the
role of HIV diagnostic testing in the prevention and control of HIV and
AIDS? |
| For many years, APHL’s Human Retroviral Testing Committee convened
annually to consider new developments, share data, and formulate recommendations,
but despite numerous strides in screening and diagnostic technology, there
has been no such conclave in recent years,. It is time, therefore, for
us to gather once again, share the latest information on HIV diagnostics,
and consider alternatives that will best help accomplish our common goal:
using the best that laboratory science has to offer to help combat and
control the spread of HIV. Thank you for your interest, and welcome to
the 2005 conference, HIV Testing: New Developments and Challenges. With warm personal regards,
Bernard M. Branson, M.D.
Associate Director for Laboratory Diagnostics
Division of HIV/AIDS Prevention
Centers for Disease Control and Prevention
Acknowledgements:
On behalf of Centers for Disease Control and Prevention (CDC) we would
like to express our appreciation to the following organizations for
their contributions to the success of our conference:
Association
of Public Health Laboratories
Biomeriuex
Calypte
Orasure
Trinity Biotech
SDS, Inc.
Meeting Programs
|
Monday February 28 |
7:30 – 8:30
|
Continental Breakfast, Poster Set-Up
|
| 8:30 – 8:40 |
Welcoming Remarks
Speaker: Bernie Branson, MD
Associate Director for Laboratory Diagnostics, CDC |
Scientific Session 1:
New HIV Enzyme Immunoassays |
| 8:40 – 9:10 |
Principles and Characteristics
of EIAs Recently Approved by the FDA
- Vironostika HIV-1 Plus
O Microelisa System for
the Detection of Antibodies to HIV-1, including Group O
Speaker: Chamroen Chetty, PhD
Senior manager Immunoassay R&D, bioMérieux Inc.
- Principles
and Characteristics of the Bio-Rad Genetic Systems™ HIV-1/HIV-2
Plus O EIA
Speaker: M. Kathleen Shriver, PhD
R&D Manager, Redmond Operations, Bio-Rad Laboratories
|
| 9:10 – 9:30 |
Comparing the New EIAs with Old Standbys: Validation Data
from Public Health Laboratories
Speaker: Berry Bennett, MPH
Retrovirology Section Chief,
Florida Bureau of Laboratories |
| 9:30 – 9:40 |
APHL Survey on HIV Assays Currently in Use
Speaker: Barbara Werner, PhD
Infectious Disease Consultant,
Massachusetts State Laboratory Institute |
| 9:40 – 10:00 |
Discussion
Moderator: S. Michele Owen, PhD
Chief HIV Serology and Developmental Diagnostics Laboratory, CDC |
| 10:00 – 10:30 |
Break – Poster and
Exhibit Review |
Scientific Session
2:
NAAT Testing for Acute HIV Infection
|
| 10:30 – 10:45 |
Results of donor screening with nucleic
acid amplification tests (NAT) and implications for HIV research,
diagnosis and surveillance
Speaker: Michael P. Busch, MD, PhD
Professor of Laboratory Medicine, UCSF
Director, Blood Systems Research Institute
|
| 10:45 – 11:00 |
Pooled RNA Testing of Antibody Negative
High-Risk Persons: San Francisco and Los Angeles
Speaker: Sally Liska, DrPH
Director, San Francisco Public Health Laboratory
|
| 11:00 – 11:15 |
Alternatives for Detecting Acute HIV:
RNA, p24, and
heat-dissociated p24
Speaker: Christopher D.Pilcher, MD
Assistant Professor of Medicine,
University of North Carolina at Chapel Hill
|
| 11:15 – 11:30 |
HIV NAAT Testing of HIV Antibody Negative
Samples
Speaker: Robert Myers PhD
Deputy Director,
Maryland Dept of Health and Mental Hygiene Laboratories
|
| 11:30 – 11:40 |
Screening for Primary HIV Infection:
The CDC Study
Speaker: Pragna Patel, MD, MPH
Medical Epidemiologist, Diagnostic Applications
Behavioral and Clinical Surveillance Branch, CDC
|
| 11:40 – 12:00 |
Discussion
Moderator: Amanda Smith, MPH
Epidemiologist, Diagnostic Applications
Behavioral and Clinical Surveillance Branch, CDC |
| 12:00 – 2:00 |
Lunch – Poster
and Exhibit Review
|
Scientific Session 3: Rapid HIV Testing
|
| 2:00 – 3:00 |
Panel: Roll-out and Implementation of
Rapid Testing from a Field Perspective
Speakers:
- Tony Falvo, CTL Program Coordinator, Florida Bureau of
HIV/AIDS
- Marianne Porter, BS MS, Director, Division of Laboratory
Improvement, Pennsylvania Department of Health
- Mara San
Antonio Gaddy, RN, MSN, Director, Bureau of Direct Program
Operations, New York State Department of Health
- Susanne
Norris Zanto, BS, CLS (NCA), Technical Services Manager,
Montana Public Health Laboratory
- Shelley Facente, MPH, HIV
Rapid Testing Coordinator, San Francisco Department of
Public Health AIDS Office
|
| 3:00 – 3:30 |
Discussion
Moderator: Bernie Branson, MD
|
| 3:30 – 4:00 |
Break – Poster
and Exhibit Review
|
| 4:00 – 4:20 |
Resolution of Discordant
Confirmatory Results after POC Reactive Rapid Tests
Speaker:
Berry Bennett, MPH
Retrovirology Section Chief,
Florida Bureau of Laboratories
|
| 4:20 – 4:40 |
Post Marketing Surveillance of OraQuick
Rapid HIV Testing
Speaker: Laura Wesolowski, MPH
Laboratory Determinants and diagnostics,
Behavioral and Clinical Surveillance Branch, CDC
|
| 4:40 – 5:00 |
Evaluation and Implementation of HIV
Rapid Tests: The Experience in Eleven African Countries
Speaker: Stefan Wiktor, MD, MPH, Chief,
Surveillance and Infrastructure Development Branch,
Global AIDS Program, CDC
|
| 5:00 – 5:30 |
Implications for the Public Health Laboratory
from Expansion of Rapid Testing
Speaker: Arthur Kazianis, BA
HIV/Hepatitis Laboratory Supervisor,
Massachusetts Department of Public Health
|
| 5:30 – 6:00 |
Discussion
Moderator: Bernie Branson, MD
|
| 6:00 – 7:30 |
Networking Reception – Poster/Exhibit
Area
|
Tuesday March 1 |
| 7:30 – 8:30 |
Continental Breakfast – Poster
and Exhibit Review
|
Scientific
Session 4:
Options for Confirmatory Testing in Different Settings
|
| 8:30 – 8:45 |
Challenges for Blood Donor Confirmatory
Testing Algorithms
Speaker: Susan L. Stramer, PhD
Executive Scientific Officer, American Red Cross
|
| 8:45 – 9:00 |
Comparison of Currently Available Assays
that Detect Human Immunodeficiency Virus to Address Alternative
Screening/Diagnostic Algorithms for HIV
Speaker: S. Michele Owen, PhD
Chief HIV Serology and Developmental Diagnostics Lab,
CDC
|
| 9:00 – 9:15 |
Performance of Rapid HIV Tests Singly
and in Combination
Speaker: Kevin Delaney, MPH
Epidemiologist, Diagnostic Applications,
Behavioral and Clinical Surveillance Branch, CDC
|
| 9:15 – 9:30 |
HIV 1/2 Combination Screening and Outcomes
of Follow-Up
Speaker: William R. Oleszko, PhD
Acting Associate Director, Public Health Laboratory,
New York City Department of Health and Mental Hygiene
|
| 9:30 – 10:00 |
Discussion of Next Steps:
Moderator: Sheryl Lyss, MD
Medical Officer, Diagnostic Applications,
Behavioral and Clinical Surveillance Branch, CDC
|
| 10:00 – 10:30 |
Break – Poster and Exhibit Review |
Scientific
Session 5: Dried Blood Spot Testing
|
| 10:30 – 10:50 |
Dried Blood Spots: An Ideal Specimen
for HIV Serologic and Nucleic Acid Testing
Speaker: Joanne Mei, PhD
Lead Research Chemist
Newborn Screening Quality Assurance Program,
CDC |
| 10:50 – 11:10 |
Usefulness and Application of Dried Blood
Spots in HIV and HCV Epidemiology, Diagnostics and Drug Resistance
Testing
Speaker: John Kim, PhD
Chief, National HIV Reference Lab
Public Health Agency of Canada |
| 11:10 – 11:30 |
Early Diagnosis of HIV-1 Infection in
Infants Using Dried Blood Spots and Real Time, RT-PCR
Speaker: Chin-Yih Ou, PhD
Chief, HIV Molecular Diagnostics Lab, CDC |
| 11:30 – 11:45 |
Use of DBS with BED Testing for Recent
Infection
Speaker: Bharat S. Parekh, PhD
Chief, HIV Incidence Laboratory, CDC |
| 11:45 – 12:00 |
Use of DBS for HIV Drug Resistance Surveillance
Speaker: Diane V. Bennett, MD, MPH, M.ED.
Coordinator, Antiretroviral Drug Resistance
Surveillance, CDC |
| 12:00 – 12:30 |
Discussion
Moderator: Joanne Mei, PhD
Lead Research Chemist, Newborn Screening Quality
Assurance Program, CDC |
| 12:30 – 2:00 |
Lunch and Networking |
Scientific Session
6: Concurrent Discussion Groups
|
| 2:00 – 2:30 |
Updates: Status of Tests
for Recent Infection & CDC’s
Plans for the Detuned IND
Speaker: Bernie Branson, MD
Associate Director for Laboratory Diagnostics, CDC |
| 2:30 – 3:30 |
Panel: Tests for Recent Infection
Moderators:
Niel Constantine and Anne M. Sill
- Calibration, validation
and application of the BED assay for recent HIV-1 infection
in multiple subtypes
Panelist: Bharat S. Parekh, PhD, Chief, HIV Incidence and
Diagnosis
Laboratory, CDC,
- A Simple and Inexpensive Algorithm for
Determining Recent HIV Infection: Development of a Sensitive/Less
Sensitive
(S/LS) Particle Agglutination Assay
Panelist: Neil Constantine, PhD, Professor, University
of Maryland School of Medicine
- Identification of Factors
Impacting the Determination of HIV Incidence in Non-Research-Based,
Clinical Populations
Panelist: Anne M. Sill, BA, Research Supervisor, Research
Associate, Institute of Human Virology,
- Incidence Tests
for the Serological Testing Algorithm for Recent HIV
Seroconversion (STARHS)
Panelist: Joanne Mei, PhD, Lead Research Chemist, CDC,
- Summary of STARHS meeting in Bangkok
Panelist: Robert Remis, MD, MPH, FRCPC, Professor,
Public Health Sciences, University of Toronto, Canada
|
| 3:30 – 4:30 |
IND Investigators Meeting |
Scientific
Session 6: Concurrent Discussion Groups |
| 2:30 – 4:30 |
Panel: Rapid HIV Testing in International
Settings
Moderator: Mark Rayfield, PhD, Global AIDS Program CDC
- Arguments
for the use HIV Rapid Tests on a National Scale in Resource
Poor Settings
Panelist: Kyle B. Bond, MS, Surveillance and Infrastructure
Development Branch, GAP, NCHSTP, CDC
- HIV in Botswana;
Improving Lab Capacity in the Face of the AIDS Pandemic
Panelist: Patricia Clark, MPH, Interim Virology/Immunology
Section Manager, Michigan Department of Community Health
- Rapid
Testing: The Kenya Experience
Panelist: Dr. Peter Tukei, Assistant Director Kenya Medical
Research Institute, Laboratory Director, CDC/KEMRI
- Use
of Rapid HIV Assays in Vietnam and Cambodia: Challenges
to improving access, quality and timeliness
of HIV Testing
Panelist: Ralph Timperi, MPH, Director Massachusetts
State Laboratory Institutes
- Quality Assurance for Rapid
Testing
Panelist: Elizabeth Dax, AM, MD, BS, PhD, Director, National
Serology Reference Laboratory, Australia
|
| 4:30 – 5:30 |
Meeting wrap-up and discussion of next
steps
Bernie Branson, MD
Associate Director for Laboratory Diagnostics, CDC |
|
|
| |
Last Update: April 8, 2005 |
|
